Avid Bioservices Inc (CDMO)

[biopharm]

Thanks Jakedogman1 and it would be of interest to have darzalex vs Bavituximab or other PS Targeting drugs side by side ....monitoring with a Keen Eye on the mechanism of actions of each and we shall see possibly, why Halozyme had chosen Avid as a key manufacturing facility for Billions of future revenue

____

________

CD38 is expressed on hematopoietic cells, other cell types and tissues, and is overexpressed on multiple myeloma cells1,2
DARZALEX® inhibits tumor cell growth through immune-mediated, direct on-tumor, and immunoregulatory actions.

DARZALEX® may also have an effect on normal cells1

https://www.darzalexhcp.com/mechanisms-of-action

_______________

If one drug such as Darzalex kicks off a series of events and flipping PS exists...well, one normally had to unlock the same series of events in reverse

So it would be of interest to see those MOA of many drugs and what happens if Targeting flipped PS is the FIRST order of event that takes place?

I have an idea....many sabotage attempts take place to delay its acceptance and maybe we now know why all the excitement over PS Targeting

_______________

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Fabio Morandi1*,
Alberto L. Horenstein2,3,
Federica Costa4,
Nicola Giuliani4†,
Vito Pistoia5† and
Fabio Malavasi2,3†

1Stem Cell Laboratory and Cell Therapy Center, Istituto Giannina Gaslini, Genoa, Italy

2Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino, Italy

3CeRMS, University of Torino, Torino, Italy

4Department of Medicine and Surgery, University of Parma, Parma, Italy

5Immunology Area, Pediatric Hospital Bambino Gesù, Rome, Italy
...
...

Anti-CD38 mAbs
Development of mAbs against CD38 started in 1990 and anti-CD38 mAbs have been tested as immunotherapeutic strategy for MM patients, so far with limited beneficial effects. The anti-tumor effect of anti-CD38 mAbs is related to their ability to induce ADCC, CDC and ADCP of opsonized CD38+ cells. Moreover, anti-CD38 mAbs can induce a direct apoptosis of CD38+ MM cells via Fc-? receptor-mediated crosslinking (24). Crosslinking of anti-CD38 mAbs on MM cells leads to clustering of cells, phosphatidylserine translocation, loss of mitochondrial membrane potential, and loss of membrane integrity.
...
...
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02722/full